Archive for 2009

Aspen’s revenue increases by 80 percent as international business expands

Johannesburg – JSE listed Aspen Pharmacare Holdings Limited, Africa’s largest pharmaceutical manufacturer, has produced excellent results for the year ended 30 June 2009. Prevailing global economic conditions did little to deter the strength of the Group’s performance, with the South African and Australian businesses continuing to perform well. Aspen’s international expansions resulted in substantially increased…

Read More

Aspen’s S26 Assurance of Quality

A message from Aspen Group Chief Executive, Stephen Saad, to the mothers of South Africa’s babies: “At Aspen we understand that the wellbeing of your baby is of utmost importance. I confidently give you my assurance that Aspen’s S26 infant milk formula available to you in South Africa is of the highest quality. My confidence is…

Read More

Quality of S-26 in South Africa Guaranteed

Johannesburg: Aspen Nutritionals, manufacturer of S-26 and other infant milk formulations (IMFs), confirms that all IMFs manufactured and marketed by Aspen Nutritionals are safe for infant consumption. This statement is being issued in response to a media report concerning the Tanzanian Food and Drug Administration’s withdrawal notification of a consignment of S-26, which, until proven…

Read More

Official statement regarding the alleged purchase transactions entered into between Aspen and Frankel Chemicals

OFFICIAL STATEMENT REGARDING THE ALLEGED PURCHASE TRANSACTIONS ENTERED INTO BETWEEN ASPEN AND FRANKEL CHEMICALS FOR THE PURCHASE BY ASPEN FROM FRANKEL CHEMICALS OF RAW MATERIALS FOR THE MANUFACTURE OF ANTI-RETROVIALS. ASPEN PHARMACARE HOLDINGS LIMITED AND ITS AFFILIATES (“Aspen”) AND FRANKEL CHEMICALS (“Frankel”) It has come to the attention of Aspen that information allegedly pertaining to…

Read More

Aspen and GSK agree on Strategic Deals

Press Conference Presentation <Click to download> SENS Announcement <Click to download> The Transactions comprise: The acquisition of the rights to distribute GSK products in South Africa by Aspen’s wholly owned subsidiary, Pharmacare Limited (“the SA Component”); The formation of a collaboration arrangement in relation to the marketing and selling of prescription pharmaceutical products in sub-Saharan…

Read More

Aspen’s offshore operations drive an impressive 91% revenue increase

Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has recorded strong revenue growth for the six months ended 31 December 2008. The positive returns were stimulated by Aspen’s recently expanded international operations. The existing businesses in South Africa and Australia have once again recorded sustained growth. Revenue increased by 91 percent to R4…

Read More

Trading Update

Aspen shareholders are hereby advised that earnings per share, for the 6 months ended 31 December 2008, are forecast to exceed those reported in the comparative period ended 31 December 2007, by 45-60%. Headline earnings per share are forecast to exceed those of the comparative period by 65-80%. As anticipated, a strong contribution from Aspen’s…

Read More

Aspen Appoints Noel Guliwe as Chief Executive in South Africa

JOHANNESBURG: Aspen Holdings is pleased to announce the appointment by its principal South African subsidiary of Noel Guliwe as Chief Executive: South Africa with effect from January 12, 2009. “The rapid globalization of the Aspen Group has necessitated increased attention from Aspen’s senior executives. Consequently, this appointment has been made to ensure that the local…

Read More